Haloperidol uses

As with all antipsychotic agents Haloperidol has been associated with persistent dyskinesias.  Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may appear in some patients on long-term therapy or may occur after drug therapy has been discontinued.  The risk appears to be greater in elderly patients on high-dose therapy, especially females.  The symptoms are persistent and in some patients appear irreversible.  The syndrome is characterized by rhythmical involuntary movements of tongue, face, mouth or jaw (., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements).  Sometimes these may be accompanied by involuntary movements of extremities and the trunk.

The influence of renal impairment on the pharmacokinetics of haloperidol has not been evaluated. About one-third of a haloperidol dose is excreted in urine, mostly as metabolites. Less than 3% of administered haloperidol is eliminated unchanged in the urine. Haloperidol metabolites are not considered to make a significant contribution to its activity, although for the reduced metabolite of haloperidol, back-conversion to haloperidol cannot be fully ruled out. Even though impairment of renal function is not expected to affect haloperidol elimination to a clinically relevant extent, caution is advised in patients with renal impairment, and especially those with severe impairment, due to the long half-life of haloperidol and its reduced metabolite, and the possibility of accumulation (see section ).

Given these considerations, antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that 1) is known to respond to antipsychotic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

Each white, film-coated, delayed-release tablet imprinted with the pink image of a pregnant woman contains doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg. Nonmedicinal ingredients: ammonium hydroxide, n-butyl-alcohol, carnauba wax powder, colloidal silicon dioxide, croscarmellose sodium, FD&C Red No. 27, denatured alcohol, FD&C Blue No. 2, hypromellose, isopropyl alcohol, magnesium stearate, magnesium trisilicate, methacrylic copolymer acid, microcrystalline cellulose 102, PEG 400, PEG 8000, polysorbate 80, propylene glycol, shellac glaze, simethicone, sodium bicarbonate, sodium lauryl sulfate, talc, titanium dioxide and triethyl acetate. Gluten-, lactose-, sulfite-, and tartrazine-free.

Haloperidol uses

haloperidol uses

Each white, film-coated, delayed-release tablet imprinted with the pink image of a pregnant woman contains doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg. Nonmedicinal ingredients: ammonium hydroxide, n-butyl-alcohol, carnauba wax powder, colloidal silicon dioxide, croscarmellose sodium, FD&C Red No. 27, denatured alcohol, FD&C Blue No. 2, hypromellose, isopropyl alcohol, magnesium stearate, magnesium trisilicate, methacrylic copolymer acid, microcrystalline cellulose 102, PEG 400, PEG 8000, polysorbate 80, propylene glycol, shellac glaze, simethicone, sodium bicarbonate, sodium lauryl sulfate, talc, titanium dioxide and triethyl acetate. Gluten-, lactose-, sulfite-, and tartrazine-free.

Media:

haloperidol useshaloperidol useshaloperidol useshaloperidol useshaloperidol uses

http://buy-steroids.org